AstraZeneca Withdraws EU Application for Lung Cancer Drug

AstraZeneca ( (GB:AZN) ) has shared an update.

AstraZeneca and Daiichi Sankyo have withdrawn their EU marketing application for datopotamab deruxtecan for advanced nonsquamous non-small cell lung cancer following feedback from the European Medicines Agency. Despite this, they remain committed to advancing this treatment through ongoing clinical trials and are continuing to pursue its potential in various lung cancer settings. The withdrawal highlights the challenges in bringing new cancer therapies to market and underscores the companies’ resilience in exploring further development opportunities for this investigational drug.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, specializing in the discovery, development, and commercialization of prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals. The company’s products are available in over 125 countries, serving millions of patients worldwide.

YTD Price Performance: -1.12%

Average Trading Volume: 2,667,942

Technical Sentiment Consensus Rating: Sell

Current Market Cap: £159B

See more data about AZN stock on TipRanks’ Stock Analysis page.